Ivana Krajsová

Ivana Krajsová

Auto-generated profile, based on publicly available information

Ivana Krajsová

General Teaching Hospital in Prague 10 , Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Caroline RobertCaroline Robert
Caroline Robert
BKBoguslawa Karaszewska
Boguslawa Karaszewska
JSJacob Schachter
Jacob Schachter
Piotr RutkowskiPiotr Rutkowski
Piotr Rutkowski
AMAndrzej Mackiewicz
Andrzej Mackiewicz
DSDirk Schadendorf
Dirk Schadendorf
The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients. In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib (960 mg twice daily) orally as first-line therapy. The primary end point was overall survival. At the preplanned interim overall survival analysis, which was performed after 77% of the total number of expected events occurred, the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). The prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014. Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). The objective response rate was 64% in the combination-therapy group and 51% in the vemurafenib group (P<0.001). Rates of severe adverse events and study-drug discontinuations were similar in the two groups. Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy group and 18% of those in the vemurafenib group. Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01597908.)

1 April 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
JLJames Larkin
James Larkin
MVMichele Del Vecchio
Michele Del Vecchio
PAPaolo A Ascierto
Paolo A Ascierto
IKIvana Krajsova
Ivana Krajsova
JSJacob Schachter
Jacob Schachter
CBChristian U Blank
Christian U Blank

1 September 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
CRC. Robert
C. Robert
BKB. Karaszewska
B. Karaszewska
JSJ. Schachter
J. Schachter
PRP. Rutkowski
P. Rutkowski
AMA. Mackiewicz
A. Mackiewicz
DSD. Schadendorf
D. Schadendorf

Verified
Journal Article
Open access
PDF file
OKOndrej Kodet
Ondrej Kodet
KNKristyna Nemejcova
Kristyna Nemejcova
Karolina StrnadovaKarolina Strnadova
Karolina Strnadova
AHAndrea Havlínová
Andrea Havlínová
PDPavel Dundr
Pavel Dundr
Lukas LacinaLukas Lacina
Lukas Lacina
Therapy targeting immune checkpoints represents an integral part of the treatment for patients suffering from advanced melanoma. However, the mechanisms of resistance are responsible for a lower therapeutic outcome than expected. Concerning melanoma, insufficient stimulation of the immune system by tumour neoantigens is a likely explanation. As shown previously, radiotherapy is a known option for increasing the production of tumour neoantigens and their release into the microenvironment. Consequently, neoantigens could be recognized by antigen presenting cells (APCs) and subjected to effector T lymphocytes. Enhancing the immune reaction can trigger the therapeutic response also at distant metastases, a phenomenon known as an abscopal effect (from “ab scopus”, that is, away from the target). To illustrate this, we present the case of a 78-year old male treated by anti-CTLA-4/ipilimumab for metastatic melanoma. The patient received the standard four doses of ipilimumab administered every three weeks. However, the control CT scans detected disease progression in the form of axillary lymph nodes metastasis and liver metastasis two months after ipilimumab. At this stage, palliative cryotherapy of the skin metastases was initiated to alleviate the tumour burden. Surprisingly, the effect of cryotherapy was also observed in untreated metastases and deep subcutaneous metastases on the back. Moreover, we observed the disease remission of axillary lymph nodes and liver metastasis two months after the cryotherapy. The rarity of the abscopal effect suggests that even primed anti-tumour CD8+ T cells cannot overcome the tumour microenvironment’s suppressive effect and execute immune clearance. However, the biological mechanism underlying this phenomenon is yet to be elucidated. The elicitation of a systemic response by cryotherapy with documented abscopal effect was rarely reported, although the immune response induction is presumably similar to a radiotherapy-induced one. The report is a combination case study and review of the abscopal effect in melanoma treated with checkpoint inhibitors.

1 April 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
LKLidija Kandolf
Lidija Kandolf
KPK. Peris
K. Peris
AHA. Hauschild
A. Hauschild
ASA. Stratigos
A. Stratigos
JGJ.-J. Grob
J.-J. Grob
Claus GarbeClaus Garbe
Claus Garbe